Neogenomics (NEO) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to -$0.21.
- Neogenomics' EPS (Weighted Average and Diluted) fell 5000.0% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.88, marking a year-over-year decrease of 4426.23%. This contributed to the annual value of -$0.62 for FY2024, which is 1120.52% up from last year.
- Neogenomics' EPS (Weighted Average and Diluted) amounted to -$0.21 in Q3 2025, which was down 5000.0% from -$0.35 recorded in Q2 2025.
- Over the past 5 years, Neogenomics' EPS (Weighted Average and Diluted) peaked at $0.59 during Q2 2021, and registered a low of -$0.4 during Q1 2022.
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.18, with a median of -$0.19 in 2021.
- Within the past 5 years, the most significant YoY rise in Neogenomics' EPS (Weighted Average and Diluted) was 108333.33% (2021), while the steepest drop was 52500.0% (2021).
- Over the past 5 years, Neogenomics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.35 in 2021, then soared by 48.57% to -$0.18 in 2022, then skyrocketed by 38.89% to -$0.11 in 2023, then fell by 9.99% to -$0.12 in 2024, then tumbled by 73.57% to -$0.21 in 2025.
- Its last three reported values are -$0.21 in Q3 2025, -$0.35 for Q2 2025, and -$0.2 during Q1 2025.